jenny mollen glp 1 Ends Up In ER After Microdosing GLP1 Medication Jason Biggs, Jenny Mollen team

What happened Researchers presenting at ENDO 2026 in Chicago on June 13, 2026 found that adults with obesity who started a GLP-1 receptor agonist drugs like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, or dulaglutide became noticeably less physically active after beginning treatment

We reduced the dose of liraglutide from 0.1 to 0.025 mg/kg body weight and repeated the same experiments

Ive definitely heard reports of improved menstrual cycles from users taking GLP-1s, specifically the return of regular menstrual cycles in people who may have skipped their periods due to anovulation (ovulation does not occur) in the setting of PCOS and obesity

Los participantes que usaron este medicamento perdieron hasta un 22,1% ms de su peso inicial despus de 48 semanas en comparacin con los participantes que tomaron placebo

doi: 10.1097/01.NAJ.0001016352.54091.a1

By lowering plasma glucose levels and body weight, metformin improves the metabolic profile of the patient and thereby reduces the severity and risk of other diseases associated with diabetes such as cardiovascular, cancer, and also neurodegenerative diseases (267)